Top-Rated StocksTop-RatedNASDAQ:ROIV Roivant Sciences (ROIV) Stock Price, News & Analysis $11.78 -0.01 (-0.08%) (As of 10:47 AM ET) Add Compare Share Share Today's Range$11.67▼$11.8550-Day Range$10.17▼$11.7952-Week Range$8.24▼$13.24Volume666,681 shsAverage Volume5.72 million shsMarket Capitalization$8.70 billionP/E Ratio2.33Dividend YieldN/APrice Target$17.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Roivant Sciences alerts: Email Address Roivant Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside45.0% Upside$17.10 Price TargetShort InterestBearish9.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.12) to ($1.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.14 out of 5 starsMedical Sector546th out of 924 stocksPharmaceutical Preparations Industry245th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRoivant Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Roivant Sciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.34% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Roivant Sciences has recently increased by 1.84%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ROIV. Previous Next 2.8 News and Social Media Coverage News SentimentRoivant Sciences has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Roivant Sciences this week, compared to 5 articles on an average week.Search Interest10 people have searched for ROIV on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.MarketBeat Follows9 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Roivant Sciences is held by insiders.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Roivant Sciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Roivant Sciences are expected to decrease in the coming year, from ($1.12) to ($1.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is 2.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.35.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is 2.33, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.87.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Roivant Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Darwin2024's Must-Watch Stocks!Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] About Roivant Sciences Stock (NASDAQ:ROIV)Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Read More ROIV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ROIV Stock News HeadlinesAugust 22 at 3:19 AM | seekingalpha.comRoivant Sciences: Inherently Risky Business Model, But Track Record ImpressesAugust 20 at 5:02 AM | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) Given Buy Rating at HC WainwrightAugust 22, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.August 18, 2024 | finance.yahoo.comIMVT Sep 2024 31.000 put (IMVT240920P00031000)August 18, 2024 | finance.yahoo.comIMVT Sep 2024 27.000 call (IMVT240920C00027000)August 17, 2024 | finance.yahoo.comIMVT Sep 2024 24.000 call (IMVT240920C00024000)August 17, 2024 | finance.yahoo.comIMVT Sep 2024 29.000 put (IMVT240920P00029000)August 17, 2024 | msn.com"Future World No. 1" - Ben Shelton earns controversial Republican leader Vivek Ramaswamy's plaudits amid stellar Cincinnati Open 2024 runAugust 22, 2024 | Crypto 101 Media (Ad)This Crypto Is Set to Explode in AugustWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Industry Giants are Investing Heavily in Blockchain Technology and THIS COIN is at the Heart of Their Strategy. It's a groundbreaking opportunity that could be poised for extraordinary gains. August 16, 2024 | americanbankingnews.comInvestors Buy Large Volume of Call Options on Roivant Sciences (NASDAQ:ROIV)August 14, 2024 | benzinga.comEstrella Immunopharma (NASDAQ:ESLAW) Stock Quotes, Forecast and News SummaryAugust 14, 2024 | ca.finance.yahoo.comIMVT Oct 2024 34.000 callAugust 9, 2024 | finance.yahoo.comQ1 2025 Roivant Sciences Ltd Earnings CallAugust 8, 2024 | markets.businessinsider.comReiterating Buy Rating on Roivant Sciences Amidst Promising Clinical Developments and Anticipated Sales GrowthAugust 8, 2024 | seekingalpha.comRoivant Sciences Ltd. 2024 Q1 - Results - Earnings Call PresentationAugust 7, 2024 | markets.businessinsider.comRoivant Sciences is about to announce its earnings — here's what to expectJuly 22, 2024 | techcrunch.comLavish parties and moral dilemmas: 4 days with Silicon Valley’s MAGA elite at the RNCJuly 21, 2024 | yahoo.comLavish parties and moral dilemmas: 4 days with Silicon Valley's MAGA elite at the RNCSee More Headlines Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today8/22/2024Next Earnings (Estimated)11/11/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ROIV CUSIPN/A CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees860Year FoundedN/APrice Target and Rating Average Stock Price Target$17.10 High Stock Price Target$23.00 Low Stock Price Target$12.00 Potential Upside/Downside+45.2%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$5.06 Trailing P/E Ratio2.33 Forward P/E RatioN/A P/E GrowthN/ANet Income$4.35 billion Net Margins3,484.86% Pretax Margin3,408.33% Return on Equity-25.05% Return on Assets-20.98% Debt Debt-to-Equity Ratio0.07 Current Ratio25.24 Quick Ratio25.24 Sales & Book Value Annual Sales$158.30 million Price / Sales54.97 Cash FlowN/A Price / Cash FlowN/A Book Value$7.99 per share Price / Book1.47Miscellaneous Outstanding Shares738,722,000Free Float704,741,000Market Cap$8.70 billion OptionableOptionable Beta1.24 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Matthew Gline (Age 40)CEO & Director Comp: $1.77MDr. Eric Venker M.D. (Age 37)Pharm.D., President & COO Comp: $1.28MDr. Mayukh Sukhatme M.D. (Age 48)President, Chief Investment Officer & Director Comp: $1.72MMr. Richard Pulik (Age 45)Chief Financial Officer Ms. Rakhi Kumar (Age 44)Chief Accounting Officer Dr. Huafeng Xu Ph.D.Chief Technology OfficerMr. Jo ChenGeneral CounselMs. Kelly GraffHead of PeopleMs. Marianne L. Romeo (Age 56)Head of Global Transactions & Risk Management Mr. Alex GasnerExecutive Vice President of Roivant HealthMore ExecutivesKey CompetitorsModernaNASDAQ:MRNABioNTechNASDAQ:BNTXTeva Pharmaceutical IndustriesNYSE:TEVABeiGeneNASDAQ:BGNEGenmab A/SNASDAQ:GMABView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Bought 185,226 shares on 8/19/2024Ownership: 0.088%Algert Global LLCSold 102,329 shares on 8/16/2024Ownership: 0.006%Quarry LPBought 5,000 shares on 8/16/2024Ownership: 0.001%The Manufacturers Life Insurance Company Sold 77,925 shares on 8/15/2024Ownership: 0.044%Point72 Hong Kong LtdBought 3,444 shares on 8/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ROIV Stock Analysis - Frequently Asked Questions How have ROIV shares performed this year? Roivant Sciences' stock was trading at $11.23 at the beginning of the year. Since then, ROIV shares have increased by 5.0% and is now trading at $11.79. View the best growth stocks for 2024 here. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) issued its quarterly earnings results on Thursday, August, 8th. The company reported $0.12 EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.33. The business's revenue for the quarter was up 155.1% compared to the same quarter last year. Who are Roivant Sciences' major shareholders? Roivant Sciences' top institutional investors include Rubric Capital Management LP (3.11%), DME Capital Management LP (0.65%), BlackBarn Capital Partners LP (0.42%) and Troluce Capital Advisors LLC (0.40%). Insiders that own company stock include Pharma Technologies Ltd Dexcel, Sciences Ltd Roivant, Svf Investments (Uk) Ltd, Vivek Ramaswamy, Financial Lp Qvt, Keith S Manchester, Matthew Gline, Global Investors Lp Viking, Eric Venker, Richard Pulik and Rakhi Kumar. View institutional ownership trends. How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ROIV) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredThis One stock is all you need...What if you could ignore 99% of the stock market... And retire on just ONE ticker?Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
